Mark Spyvee Email & Phone Number

Founder of a consulting firm offering drug discovery and preclinical development guidance. Roles include project selection and portfolio oversight, medchem problem solving, rational drug design, computational chemistry, process R&D, value proposition assessment, due diligence, fund raising, patent strategy and documentation, CRO management, project.

Canton, MA, US

Leading medicinal chemistry and drug development to address unmet medical needs in oncology, immunology, infectious diseases and organ transplantation. Heavy emphasis placed on FBDD, computationally-guided optimization of small molecules, and leveraging in-house co-crystal X-ray structures. Responsibilities include establishing and leading external.

Cambridge, MA, US

Led medicinal chemistry and rational drug design activities for internal oncology R&D projects. Focused on implementing and optimizing in-house expertise in artificial intelligence and computational chemistry. Responsibilities included establishing and managing external chemistry, biology and DMPK collaborations in Europe and Asia.

Belfast, GB

Inventing drug molecules for the treatment of cancer and inflammatory conditions including CV6-168 which has completed pre-clinical development and about to enter clinical trials. Responsibilities include leadership of medicinal chemistry, pharmacology, process R&D and managing external collaborations.

Gachibowli, Hyderabad, Telangana, IN

Provided scientific and strategic guidance to 37 clients in the USA & UK for integrated drug R&D programs. Responsibilities included refining scientific services business strategy and generation of new business. Supported 18 collaborations generating >$20MM in revenue and spearheaded a risk-sharing collaboration with a VC firm to create a start-up focused.

Nutley, NJ, US

• Executive team member of Immunology R&D comprising 115 colleagues in Japan, US, & UK, reporting to the Unit President. Co-led a 60-member international discovery group, responsible for producing drug candidates for.
• Oversaw advancement of 3 compounds into preclinical development for autoimmune diseases.
• Delivered 3 additional series of compounds to neuroscience & oncology pipelines.
• Motivated teams to successfully compress project timelines 50% over expectations.
• Revised discovery strategies to align with evolving patient needs.
• Forged strategic alliances via CROs, KOLs & other partnerships to improve productivity.

Nutley, NJ, US

• Sr. Principal Scientist <- Sr. Scientist <- Scientist <- Sr. Research Investigator <- Research Investigator Led group of 5 Medicinal Chemists, reporting to the chemistry department head. Instigator & leader of an.
• Advanced 2 compounds from early discovery through IND-enabling studies, as global team leader
• Helped deliver other candidates for malaria, RA, psoriasis, cancer & infection
• Championed other projects through early discovery milestones: sepsis, IBD & MS
• Achieved project milestones in half the anticipated time frames

Basel, Basel, CH

• Designed & synthesized novel kainoids as potent insecticides

• Synthetic organic chemist, lab safety coordinator & supervisor of 2 associate-level scientists
• Contributed to a fungicide project that resulted in the billion $ product AMISTAR (azoxystrobin)
• Instrumental in the discovery & advancement of other fungicidal compounds to development
• Investigated & optimized compounds as plant growth regulators

Nottingham, GB

• Process chemistry for the heart drug Manoplax (flosequinan)

• Research of novel materials for the lining of blast furnaces, space shuttles & other applications

• Analytical QC chemist

D.Phil / Ph.D, Synthetic Organic Chemistry

Postdoctoral Fellow, Synthetic Organic Chemistry